Ilyang Pharmaceutical Co.,Ltd (KRX: 007570)

Ilyang Pharmaceutical Co.,Ltd Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	366,053	370,537	383,811	371,348	343,329	324,573
Other Revenue	0	-	-	-	-	0
Revenue	366,053	370,537	383,811	371,348	343,329	324,573
Revenue Growth (YoY)	-3.84%	-3.46%	3.36%	8.16%	5.78%	8.18%
Cost of Revenue	171,283	170,520	167,960	167,054	161,690	145,915
Gross Profit	194,770	200,017	215,851	204,293	181,638	178,658
Selling, General & Admin	140,360	143,179	147,306	139,430	124,701	127,549
Research & Development	26,988	27,439	25,960	20,196	19,723	15,850
Other Operating Expenses	3,183	3,692	1,911	1,832	1,944	1,650
Operating Expenses	171,769	175,204	175,444	163,268	147,538	146,147
Operating Income	23,001	24,813	40,408	41,025	34,101	32,511
Interest Expense	-3,570	-3,691	-2,459	-2,058	-3,017	-4,235
Interest & Investment Income	542.74	390.62	1,010	938.83	516.99	340.71
Earnings From Equity Investments	-14,556	-16,500	-	-	-	-
Currency Exchange Gain (Loss)	354.47	-1,061	-283.07	952.78	-918.59	-214.68
Other Non Operating Income (Expenses)	-1,479	-952.36	2,696	-2,197	-354.03	-235.48
EBT Excluding Unusual Items	4,293	2,998	41,372	38,661	30,329	28,167
Gain (Loss) on Sale of Investments	18.03	8.92	-24.78	-	-123.55	0.92
Gain (Loss) on Sale of Assets	0.46	0.53	21.22	-26.46	134.47	-506.76
Asset Writedown	-4.48	40.51	-36.82	292.5	-1,947	-
Pretax Income	4,307	3,048	41,331	38,927	28,393	27,661
Income Tax Expense	649.42	2,936	9,590	12,972	6,847	8,066
Earnings From Continuing Operations	3,658	111.71	31,741	25,956	21,545	19,595
Minority Interest in Earnings	-3,095	-2,658	-12,503	-11,572	-10,666	-9,610
Net Income	562.48	-2,546	19,238	14,384	10,880	9,985
Preferred Dividends & Other Adjustments	-79.09	-79.09	449.28	-	-	-
Net Income to Common	641.57	-2,467	18,789	14,384	10,880	9,985
Net Income Growth	-93.67%	-	33.75%	32.21%	8.96%	-
Shares Outstanding (Basic)	18	18	18	18	18	18
Shares Outstanding (Diluted)	18	18	18	18	18	18
Shares Change (YoY)	-0.58%	-0.59%	-0.44%	-	-	-0.29%
EPS (Basic)	35.70	-136.91	1036.59	790.09	597.61	548.47
EPS (Diluted)	32.57	-140.00	1036.00	790.00	597.00	548.00
EPS Growth	-93.02%	-	31.14%	32.33%	8.94%	-
Free Cash Flow	18,871	13,293	25,854	54,109	47,310	34,019
Free Cash Flow Per Share	1050.02	737.75	1426.40	2972.19	2598.70	1868.64
Dividend Per Share	150.000	150.000	-	-	-	-
Gross Margin	53.21%	53.98%	56.24%	55.01%	52.91%	55.04%
Operating Margin	6.28%	6.70%	10.53%	11.05%	9.93%	10.02%
Profit Margin	0.18%	-0.67%	4.90%	3.87%	3.17%	3.08%
Free Cash Flow Margin	5.16%	3.59%	6.74%	14.57%	13.78%	10.48%
EBITDA	35,683	38,417	53,472	53,675	46,765	42,601
EBITDA Margin	9.75%	10.37%	13.93%	14.45%	13.62%	13.13%
D&A For EBITDA	12,683	13,604	13,065	12,650	12,664	10,090
EBIT	23,001	24,813	40,408	41,025	34,101	32,511
EBIT Margin	6.28%	6.70%	10.53%	11.05%	9.93%	10.02%
Effective Tax Rate	15.08%	96.33%	23.20%	33.32%	24.12%	29.16%
Advertising Expenses	-	41,240	42,422	35,105	35,608	37,098

Source: S&P Capital IQ. Standard template. Financial Sources.